Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Current Deferred Revenue (2022 - 2025)

Oramed Pharmaceuticals' Current Deferred Revenue history spans 3 years, with the latest figure at $1.4 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue changed N/A year-over-year to $1.4 million; the TTM value through Dec 2025 reached $1.4 million, changed N/A, while the annual FY2025 figure was $1.4 million, N/A changed from the prior year.
  • Current Deferred Revenue reached $1.4 million in Q4 2025 per ORMP's latest filing, up from $986000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $2.7 million in Q1 2022 to a low of $674000.0 in Q1 2023.
  • Average Current Deferred Revenue over 3 years is $1.5 million, with a median of $1.3 million recorded in 2022.
  • The largest YoY upside for Current Deferred Revenue was 75.06% in 2023 against a maximum downside of 75.06% in 2023.
  • A 3-year view of Current Deferred Revenue shows it stood at $1.3 million in 2022, then plummeted by 49.7% to $674000.0 in 2023, then surged by 100.74% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Current Deferred Revenue are $1.4 million (Q4 2025), $986000.0 (Q3 2025), and $1.2 million (Q2 2025).